OUR VISION IS TO BE A TOP TIER INNOVATIVE ONCOLOGY DRUG DEVELOPMENT COMPANY
PharmaEngine Inc. (TWO: 4162) is a commercial stage pharmaceutical company, we focus on the development of new medical treatment of cancer, as well as the commercialization of ONIVYDE® in Taiwan. Our headquarter is in Taipei, Taiwan with a wholly owned subsidiary PharmaEngine Europe, Sarl in Paris, France.
PharmaEngine has adapted the “no research, development only model (NRDO)” as well as “networked pharma model” for new drug development. Learn more…
Our portfolio includes ONIVYDE® approved for metastatic pancreatic cancer in Taiwan, US, EU, Australia, Canada, Japan, South Korea, and Singapore; PEP06 is currently in the Phase I stage; and PEP07 in preclinical development. Learn more…